A top U.S. health official on Wednesday touted the therapeutic potential of psychedelics like psilocybin and MDMA, and he also slammed ongoing federal restrictions that are inhibiting research into marijuana. Francis Collins, director of the National Institutes of Health (NIH), was asked about psychedelics and cannabis by Sen. Brian Schatz (D-HI) during a Senate Appropriations subcommittee hearing. The senator said there’s been “potentially promising peer-reviewed clinical research” into the substances and referenced a letter NIH sent him in 2019 that recognized the medical value of certain psychedelics. He asked for a status update on how the agency is navigating the issue.
Kyle Jaeger, Marijuana Moment, 05/26/2021 14:17:00